VERTEX PHARMACEUTICALS INC / MA - 8-K Filing
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in a $85.00 per share cash deal, totaling approximately $4.2 billion based on outstanding shares (excluding owned shares). The merger is expected to close by Q3 2026 and financed with existing cash and new debt financing including a $4.5 billion bridge loan from Bank of America and Morgan Stanley. (Items: 1.01 Entry into a Material Definitive Agreement, 7.01 Regulation FD, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $VRTX